Scientists develop tumor-specific cancer therapy

Study suggests that the new cancer immunotherapy can prevent the immune system from becoming tolerant of tumors, which occurs in 30 per cent of all cancer patients.

By: IANS | | Updated: July 13, 2019 10:59 am

There has been an alarming increase in the number of pancreas and colorectal cancer cases, globally. © Shutterstock

Chinese scientists developed a combined tumor-killing therapy that can be activated specifically at tumor sites in mouse models of cancer, which is more effective than previous similar therapies. Also Read - Kidney cancer: All you need to know about the treatment options

The study published on Friday in the journal Science Immunology described the new cancer immunotherapy that can prevent the immune system from becoming tolerant of tumors, which occurs in 30 per cent of all cancer patients, the Xinhua news agency reported. Also Read - New oral immunotherapy can be a potential treatment for egg allergy: Study

A team led by Wang Dangge from Shanghai Institute of Materia Medica under the Chinese Academy of Sciences and Fudan University developed a common immune checkpoint inhibitor in a nanoparticle formulation, which is highly tumor-specific. Also Read - Small cell lung cancer may respond to combination therapy

The checkpoint inhibitor is a kind of increasingly popular anti-tumor drug. It can block proteins that keep immune T cells from killing cancer. But the checkpoint inhibitor used to target those immune system-suppressing proteins like PD-1 and PD-L1 often fails to reach deep-seated or metastatic tumors.

Wang’s team combined the nanoparticles carrying PD-L1-targeting antibodies with a light-activated molecule. The molecule called photosensitiser can produce tumor-killing reactive oxygen species after encountering a protein abundant in tumors, according to the study.

In mouse models, a local near-infrared radiation that activated the photosensitiser, along with the administration of antibodies-carrying nanoparticles, promoted the infiltration of cancer cell-killing T cells into the tumor site and made the tumors more sensitive to the checkpoint blockade.

This combination also helped the nanoparticles effectively suppress tumor growth and metastasis to the lung and lymph nodes, resulting in approximately 80 per cent mouse survival over 70 days, compared to complete mouse death in 45 days in the group treated with only PD-L1 antibodies, according to the study.

Published : July 13, 2019 10:39 am | Updated:July 13, 2019 10:59 am

Read Disclaimer

Combination of breast and lung cancer drugs more effective in killing cancer cells: Study

Plant paradox diet: Is it really a healthy way to weight loss?

About The health Site

TheHealthSite.com is India's largest health site with more than 40 lakh unique visitors per month. We focus on fitness, beauty, health, pregnancy and more.

Most popular health and wellness website in India in 2012 at the Website of the year awards.

health@corp.india.com

+91 – 22 – 6697 1234

91 – 22 – 2490 0302.

ZEE ENTERTAINMENT ENTERPRISES LTD, 18th floor, A-Wing, Marathon Futurex, N. M. Joshi Marg, Lower Parel, Mumbai, Maharashtra 400013.

We respect your privacy

Combination of breast and lung cancer drugs more effective in killing cancer cells: Study

Plant paradox diet: Is it really a healthy way to weight loss?

Vitamin D intake may help reduce risk of colitis in patients receiving anti-cancer therapy

Prostate cancer can rely on immunotherapy for treatment: Study

Kidney cancer: All you need to know about the treatment options

New oral immunotherapy can be a potential treatment for egg allergy: Study

Small cell lung cancer may respond to combination therapy

About The health Site

Useful Links